Stifel lowered the firm’s price target on OptimizeRx (OPRX) to $8 from $13 and keeps a Buy rating on the shares after the company blamed its Q3 revenue shortfall on its DTC segment, Medicx. The stock was down 15% in after-market trading, consistent with estimate revisions, notes the firm, which expects the stock to be range-bound pending stabilization of the DTC segment and better visibility on 2025 growth.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX: